JC
Therapeutic Areas
Kinoxis Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KNX100 | Agitation and aggression associated with dementia | Phase 2 |
| KNX101 | Acute and chronic pain | Preclinical/IND‑enabling |
| KNX200 series | Stress adaptation, emotional regulation, nociception (oxytocin‑receptor partial agonists) | Preclinical |
Leadership Team at Kinoxis Therapeutics
HA
Hugh Alsop
Chief Executive Officer
MB
Michael Bowen
Chief Scientific Officer
TA
Tiina Ahveninen
Vice President, Clinical Research
TR
Tristan Reekie
Head of Chemistry
CJ
Cameron Jones
Chief Financial Officer & Company Secretary
PD
Peter Devine
Chair
KN
Kathy Nielsen
Non‑Executive Director